title: IgA as therapeutic antibody.
abstract: This review is focused on the promises of IgA as a new therapeutic antibody. For more than 30 years IgG molecules have been used in the clinic in the fields of oncology, hematology, auto immune diseases and infections. However, IgA might be a good alternative, since it recruits different effector cells, i.e. polymorphonuclear cells or neutrophils, but can also activate monocytes and macrophages. The present knowledge, but also future direction for IgA- based drugs are discussed.
authors.affiliation: Immunotherapy Laboratory, Laboratory for Translational Immunology, UMC Utrecht, The Netherlands. Electronic address: jleusen@umcutrecht.nl.
authors.forename: Jeanette H W
authors.initials: JH
authors.lastname: Leusen
mesh_terms: D000818:Animals; D018951:Antigens, CD20 / Q000235:genetics / Q000276:immunology; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001402:B-Lymphocytes / Q000187:drug effects / Q000276:immunology / Q000473:pathology; D015870:Gene Expression; D006801:Humans; D007116:Immunization, Passive / Q000379:methods*; D007070:Immunoglobulin A / Q000235:genetics / Q000276:immunology / Q000627:therapeutic use*; D007074:Immunoglobulin G / Q000235:genetics / Q000276:immunology; D008212:Lymphocyte Depletion; D008264:Macrophages / Q000276:immunology / Q000473:pathology; D051379:Mice; D009000:Monocytes / Q000276:immunology / Q000473:pathology; D009369:Neoplasms / Q000235:genetics / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D009504:Neutrophils / Q000276:immunology / Q000473:pathology; D000069283:Rituximab / Q000627:therapeutic use*
chemical_list: D018951:Antigens, CD20; D000970:Antineoplastic Agents; D007070:Immunoglobulin A; D007074:Immunoglobulin G; D000069283:Rituximab
keywords: Antibody therapy; IgA; Immunotherapy